Factors influencing best tolerated dose of pirfenidone (PFD) in patients with IPF

N. Agrawal (Mumbai, India), P. Vaidya (Mumbai, India), R. Shah (Mumbai, India), V. Chavhan (Mumbai, India), J. Leuppi (Liestal, Switzerland), A. Leuppi-Taegetmeyer (Liestal, Switzerland), P. Chhajed (Mumbai, India)

Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries

Session: Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Session type: E-poster session
Number: 1846

Disease area: Interstitial lung diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Agrawal (Mumbai, India), P. Vaidya (Mumbai, India), R. Shah (Mumbai, India), V. Chavhan (Mumbai, India), J. Leuppi (Liestal, Switzerland), A. Leuppi-Taegetmeyer (Liestal, Switzerland), P. Chhajed (Mumbai, India). Factors influencing best tolerated dose of pirfenidone (PFD) in patients with IPF. 1846

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.